RORC and T-cell non-Hodgkin lymphoma: In particular, thymic alterations and a risk of T-cell lymphoma development may emerge as a consequence of sustained pharmacological inhibition of RORγt as was observed in mice with a genetic deficiency for both RORγ/RORγt isoforms [62, 63].